From Science to Bedside: Defining the New Paradigm for Advancements in Alzheimer’s and Dementia

New York


November 8, 2022


World Economic Forum

18:50 GMT | 19:50 CET | 1:50pm EST

The near-perfect alignment of Alzheimer’s and other dementias to the aging mega-trend brings about urgency for innovation. Absent new innovations in effective therapies, diagnostics, caregiving and social framing, Alzheimer’s will continue to be a barrier to healthy aging and fiscal sustainability. However, even with great innovation, if care at the bedside is not transformed, patients will not benefit. Progress in this space will depend on value-based incentives and new paradigms for diagnosis, care and other supports. Programs like the Davos Alzheimer’s Collaborative are using implementation science tos tudy the impact of innovation in real-world settings. Panelists will describe efforts to reframe Alzheimer’s to help remove the stigma, prepare health systems, and spur innovation.


Phyllis Barkman Ferrell
Global Head, External Engagement, Alzheimer's Disease and Neurodegeneration, Eli Lilly & Company; Healthsystem Preparedness Program Lead, Davos Alzheimer’s Collaborative
Ishtar Govia
PhD, Senior Lecturer, Caribbean Institute for Health Research
Chris Lynch
Deputy CEO at Alzheimer’s Disease International (ADI) and Director of Policy, Communications & Publications
Craig W. Ritchie
Professor of the Psychiatry of Ageing, Centre for Clinical Brain Sciences, University of Edinburgh; Visiting Professor, Imperial College London
Steven R. Smith
MD, Chief Scientific Officer and Senior Vice President, AdventHealth